文献速递乳腺癌放疗放疗物理与技术

Halcyon 6X FFF 直线加速器相比传统 C 臂 FF 直线加速器提高全乳照射表浅剂量:活体剂量学与计划研究

Increase in Superficial Dose in Whole-Breast Irradiation With Halcyon Straight-Through Linac Compared With Traditional C-arm Linac With Flattening Filter: In vivo Dosimetry and Planning Study.
PubMed 文献 · Adv Radiat Oncol · 2019-08-21

该研究通过 11 例乳腺癌患者的活体剂量学测量、体模测量及 14 例患者的计划对比,评估 Halcyon 6X FFF 直线加速器全乳照射的表浅剂量。结果显示 Halcyon 6X FFF 的表浅剂量高于传统 6X FF 直线加速器,平均表浅剂量达 83.8%±0.6%,体模中从 70%±1.3% 升至 84%±1.3%,计划比较中 V70%Rx 从 62%±4.4% 升至 81%±2.2%,可能减少对 bolus 的需求。

要点

  • Halcyon 6X FFF 全乳照射活体表浅剂量平均为 83.8%±0.6%,较已发表 6X FF 数据约高 10%。
  • 体模中 6X FFF 表浅剂量从 70%±1.3% 升至 84%±1.3%,与活体测量一致。
  • 计划比较显示 Halcyon 6X FFF 表浅乳腺组织 V70%Rx 从 62%±4.4% 升至 81%±2.2%。

核心结论

  • 使用 Halcyon 6X FFF 光束与更高的表浅剂量相关,可能无需使用 bolus。

研究设计与样本

  • 活体剂量学研究纳入 11 例接受 Halcyon 6X FFF 直线加速器治疗的乳腺癌患者,使用光释光剂量计测量表浅剂量。
  • 体模研究比较 Halcyon 6X FFF 与 6X FF 光束在体模中的表浅剂量。
  • 计划研究对 14 例 Halcyon 治疗患者用传统直线加速器重新计划,比较治疗计划系统预测的表浅剂量差异。

主要发现

  • 活体测量显示平均表浅剂量为 83.8%±0.6%,较已发表的 6X FF 直线加速器测量值增加约 10%。
  • 体模测量中 6X FF 与 6X FFF 光束的表浅剂量从 70%±1.3% 增至 84%±1.3%,与活体测量一致。
  • 计划比较显示 Halcyon 6X FFF 相比标准 C 臂 FF 直线加速器,表浅乳腺组织 V70%Rx 从 62%±4.4% 增至 81%±2.2%。

关键数值与推荐

  • Halcyon 6X FFF 活体平均表浅剂量:83.8%±0.6%。
  • 体模 6X FF 表浅剂量:70%±1.3%;6X FFF 表浅剂量:84%±1.3%。
  • 计划比较表浅乳腺组织 V70%Rx:传统 C 臂 FF 为 62%±4.4%,Halcyon 6X FFF 为 81%±2.2%。

临床怎么用

  • 对于使用 Halcyon 6X FFF 行全乳照射的患者,应考虑其表浅剂量较高可能降低对 bolus 的需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Superficial dose is an important parameter in breast cancer radiation therapy. When treated with conventional linacs, bolus is commonly applied to improve target coverage near the surface while also managing the risk of severe skin reactions and negative cosmesis. With the introduction of modern linacs with 6X flattening filter free (FFF) photon beams, the effect on superficial dose and the need for bolus must be evaluated. METHODS AND MATERIALS: In vivo measurements of superficial dose were made with optically stimulated luminescence dosimeters on 11 breast cancer patients treated with the Halcyon 6X FFF linac (Varian Medical Systems, Palo Alto, CA). Additionally, measurements were made with the Halycon 6X FFF beam and a 6X beam with flattening filter (FF) delivered to an anthropomorphic phantom. A planning study was carried out in which 14 patients treated on the Halcyon were replanned with a conventional linac to determine the difference in superficial dose predicted by the treatment planning system. Measures were taken to increase the accuracy of the treatment planning system superficial dose. RESULTS: The use of the Halcyon 6X FFF beam led to higher superficial dose compared with 6X FF beams. The in vivo measurements show an average superficial dose of 83.8% ± 0.6%, which is an increase of approximately 10% compared with published measurements for a 6X FF linac. Comparison of superficial dose for 6X FF and 6X FFF beams in the phantom measurements show an increase from 70% ± 1.3% to 84% ± 1.3%, which is consistent with the in vivo measurements. The planning comparison shows an increase in V70%Rx from 62% ± 4.4% to 81% ± 2.2% for the superficial breast tissue for the Halcyon 6X FFF beam compared with a standard C-arm linac with FF. CONCLUSIONS: The use of the Halcyon 6X FFF beam was associated with higher superficial dose which may obviate the use of bolus.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. O'Grady F, Barsky AR, Anamalayil S, et al. Increase in Superficial Dose in Whole-Breast Irradiation With Halcyon Straight-Through Linac Compared With Traditional C-arm Linac With Flattening Filter: In vivo Dosimetry and Planning Study. Adv Radiat Oncol. 2019. PMID: 32051898. doi:10.1016/j.adro.2019.07.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。